Compugen Ltd.
CGENHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeCompugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United. Valued at $245.3M, CGEN is a micro-cap name in its sector. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody; COM902, a therapeutic anti-TIGIT antibody, are in Phase 1 clinical trials and have been evaluated for the treatment of solid tumors as a monotherapy and in combination of PVRIG/PD-1 and PVRIG/TIGIT, as well as PVRIG/PD-1/TIGIT blockade; Bapotulimab, a therapeutic antibody targeting ILDR2 that is evaluated in Phase I clinical trials in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti- PD-1/TIGIT bispecific antibody, which is in Phase III clinical study in patients with advanced or metastatic non-small cell lung cancer.
Market Cap
$245.3M
Beta
2.79
P/E (TTM)
6.82
P/E (Fwd)
-7.06
EPS (TTM)
$0.38
EPS (Fwd)
$-0.37
ROE
50.6%
ROA
15.5%
Cash
$125.3M
Total Debt
$3.0M
Free CF
$22.2M
52W Change
81.1%
Annual Financials
Cash vs Debt
Where CGEN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CGEN finished 13.36% above its 150-day moving average ($2.32) and 21.76% above its 200-day moving average ($2.16). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CGEN overbought or oversold?
At the September 3, 2026 close, CGEN's RSI(14) was 60.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $125.3M in cash comfortably exceeding the $3.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $22.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 50.6%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 15.5% further supports the picture of efficient asset utilization. Revenue has grown from $7.5M (2022) to $72.8M (2025), reflecting a 870% increase over the period.
A beta of 2.79 means CGEN is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, CGEN has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing CGEN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.